CVAC News and Press, CureVac N.V. From 12/13/23

2023-12-13 11:18:26 ET More on Pfizer Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Biggest stock movers tod...

2023-12-01 03:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-30 17:15:31 ET Summary CureVac N.V. has experienced a significant decline in shareholder value since going public in 2020 during the height of the covid pandemic fear. The company has a partnership with GSK plc to develop vaccines for Covid-19 and the flu, providing a sour...

thyssenkrupp AG (TYEKF) is expected to report for Q4 2023 Azul S.A. American Depositary Shares (each representing three preferred shares) (AZUL) is expected to report $-0.38 for Q3 2023 Bath & Body Works Inc. (BBWI) is expected to report $0.36 for Q3 2024 Johnson Controls Internat...

CureVac N.V. (CVAC) is expected to report $-0.26 for Q3 2023

2023-11-14 15:15:10 ET CureVac N.V. (CVAC) Q3 2023 Earnings Conference Call November 14, 2023 09:00 AM ET Company Participants Sarah Fakih - VP, Corporate Communications and IR Alexander Zehnder - CEO Pierre Kemula - CFO Myriam Mendila - CDO Marcus Dalton...

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 First participant dosed in sea...

2023-11-13 10:16:54 ET More on CureVac BV CureVac slips as court pauses mRNA patent trial against BioNTech Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV For further detai...

COVID-19 Phase 2 clinical trial fully enrolled Study compares mono- and bivalent vaccine candidates against licensed comparator COVID-19 vaccine First participant dosed in seasonal flu Phase 2 part of combined Phase 1/2 study Study compares a potentially differentiated, multivale...

2023-10-02 12:28:56 ET More on BioNTech BioNTech: Renewed COVID Focus Might Spark Potential Share Price Boost BioNTech: Not Just Another Jab In The Arm BioNTech SE (BNTX) Q2 2023 Earnings Call Transcript Updated COVID boosters to divide America Pfizer...